A new ADHD drug targets three brain chemicals instead of two. Here’s what that means
Along with dopamine and noradrenaline, this new drug also impacts levels of serotonin.
A new medication called centanafadine, marketed under the brand name Simtriyo, has been approved in the United States for treating attention-deficit hyperactivity disorder (ADHD). This drug is unique because it targets three brain chemicals - noradrenaline, dopamine, and serotonin - while most existing ADHD medications only affect two: dopamine and noradrenaline.
Centanafadine functions by slowing down the brain's reuptake process, which allows these chemicals to remain active for longer periods, thus improving communication between brain cells. The drug has shown promising results in clinical trials, but more research is needed to determine if it is more effective than existing ADHD medications. Common side effects of centanafadine include reduced appetite, insomnia, dry mouth, and headache.
Written by urgent.news from The Conversation AU's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
